Drugs

, Volume 24, Issue 5, pp 360–400

Domperidone

A Review of its Pharmacological Activity, Pharmacokinetics and Therapeutic Efficacy in the Symptomatic Treatment of Chronic Dyspepsia and as an Antiemetic
  • R. N. Brogden
  • A. A. Carmine
  • R. C. Heel
  • T. M. Speight
  • G. S. Avery
Drug Evaluations

Summary

Synopsis: Domperidone1 is a dopamine antagonist that does not readily enter the central nervous system. Given parenterally or orally it increases gastric emptying of liquids and increases lower oesophageal sphincter pressure in healthy subjects. The antiemetic and pharmacodynamic profile of domperidone is similar to that of metoclopramide, although domperidone has a lower propensity to cause extrapyramidal side effects. Domperidone effectively alleviates symptoms of chronic postprandial dyspepsia and nausea and vomiting due to a wide variety of underlying causes and in some studies has been superior to metoclopramide. Vomiting associated with the administration of moderately emetic cytotoxic drugs is controlled in the majority of patients. Alleviation of the dose-limiting peripheral side effects (nausea and vomiting) of the anti-Parkinsonian drugs bromocriptine and levodopa, enables a higher optimum dose, with consequent improvement in Parkinsonian symptoms. Domperidone does not aggravate the extrapyramidal side effects of neuroleptic drugs. Control of cytotoxic-induced, and postprandial nausea and vomiting in children has been achieved with domperidone without evidence of extrapyramidal side effects. Indeed, side effects have seldom occurred with therapeutic doses of domperidone.

Pharmacodynamic Studies: Domperidone is a dopamine antagonist with antiemetic properties similar to those of metoclopramide and certain neuroleptic drugs. Unlike these drugs, however, domperidone does not readily cross the blood-brain barrier and seldom causes extrapyramidal side effects.

The wide dissociation between the peripheral and central effects of domperidone has been clearly demonstrated in animal studies by the low brain concentrations after systemic administration, the lack of effect on plasma concentrations of the dopamine metabolite, homovanillic acid, the marked differences in the effect of intracerebrally and systemically administered domperidone in antagonising the behavioural effects of dopamine, and the wide difference in the intravenous dosage needed to antagonise the peripheral (emetic) and central effects of apomorphine.

Studies in humans have shown intravenous and oral domperidone to increase lower oesophageal sphincter pressure in healthy subjects, to increase the duration of antral and duodenal contractions, to increase the gastric emptying of liquids and semi-solids such as a barium meal, and to shorten the stationary phase for solids in healthy subjects and in patients in whom it was delayed. The effect in patients with histologically confirmed reflux oesophagitis has, however, been equivocal.

Administered orally or intravenously, domperidone is a potent stimulant of prolactin release in both males and females, although peak concentrations of prolactin are consistently higher in females than in males. The increase in plasma prolactin occurs in healthy subjects, in hyperprolactinaemia after childbirth, and in hypothyroid patients, but domperidone has little effect on plasma prolactin in patients with a prolactin-secreting tumour. Domperidone does not affect plasma growth hormone or aldosterone concentrations.

Pharmacokinetics: Peak plasma concentrations are attained at 10 to 30 minutes after intramuscular and oral administration, and at 1 to 2 hours after rectal administration of suppositories. Systemic bioavailability of intramuscular domperidone is about 90%, whereas that of oral domperidone is 13 to 17%. The low systemic bioavailability is probably due to ‘first-pass’ hepatic and gut wall metabolism. Oral bioavailability is increased when domperidone is administered 90 minutes after a meal, but is decreased by prior administration of cimetidine or sodium bicarbonate.

Distribution data in humans are lacking, but studies in rats with radiolabelled drug have shown wide distribution in body tissues except the central nervous system, where only low concentrations occur. Small amounts of radioactivity cross the placental barrier.

In humans, the apparent volume of distribution is 440L, or 5.7 L/kg, after intravenous administration. The human plasma protein binding of tritiated domperidone is about 92%.

Domperidone undergoes rapid and extensive biotransformation by hydroxylation and oxidative N-dealkylation. The proportion of the drug remaining unchanged is small, accounting for only 1.4% of the total urinary radioactivity and 10% of the faecal radioactivity. After oral administration of 40mg l4C-domperidone in healthy volunteers, 31% of the radioactivity is excreted in the urine and 60% in the faeces over a period of 4 days. Practically all of the urinary radioactivity is recovered within the first 24 hours, with only 1.4% (0.43% of the dose) present as unchanged drug. The greatest proportion of that part of the dose recovered in the urine is in the form of glucuronide conjugates of the metabolite formed by oxidative N-dealkylation. The elimination half-life of domperidone is 7.5 hours in healthy subjects and is prolonged to up to 20.8 hours in patients with severe renal dysfunction. However, since renal clearance is small compared with total plasma clearance (700 ml/minute), accumulation should not occur in renal dysfunction.

Therapeutic Trials: Domperidone has been extensively studied in the treatment of a cluster of symptoms commonly referred to as chronic dyspepsia and in the treatment and prevention of nausea and vomiting resulting from a variety of causes.

In studies comparing oral domperidone 30 to 80mg with placebo or with an equal dose of metoclopramide in patients with functional postprandial dyspepsia, domperidone has been superior to placebo where adequate numbers of patients have been studied and at least as effective as metoclopramide. Assessment has usually been by changes in symptom scores and global assessment.

Studies in patients with reflux oesophagitis confirmed by endoscopy and/or biopsy, have usually shown no difference between the effect of domperidone 30 to 80mg daily and placebo as assessed by repeat endoscopy, biopsy or acid infusion tests. However, domperidone has relieved some symptoms to a greater extent than placebo.

Preliminary studies in endoscopically confirmed gastric ulcer have reported domperidone 60mg to be more effective than placebo in promoting healing. In a single study, lasting only 3.5 weeks, no significant difference between the rates of healing with cimetidine 1g daily and domperidone 50mg daily could be detected. Further well designed studies of longer duration are needed to determine the role of domperidone in promoting healing of gastric ulcers.

Domperidone has been shown to be an effective antiemetic in patients with postoperative vomiting, when administered after the first vomiting episode. However, when administered before induction or near the end of anaesthesia, postoperative emetic sequelae have not consistently been prevented. The reasons for the indifferent efficacy of domperidone in these studies is unclear, but may be associated with the route of administration, narcotic premedication and the time between administration and the postoperative recovery period.

Nausea and vomiting associated with cytotoxic drug therapy has generally been effectively controlled by parenteral domperidone administered immediately before the cytotoxic regimen. Domperidone has usually been found to be superior to placebo and comparable with metoclopramide. As might be expected, symptoms accompanying the use of strongly emetic drugs like mustine (mechlorethamine; nitrogen mustard) and dacarbazine have been controlled less often than those associated with moderately emetic cytotoxic drugs.

In children, domperidone has been successfully used to treat cytotoxic-induced vomiting, that associated with various underlying conditions such as gastroenteritis, gastritis and acetonaemia, and acute and persistent symptoms arising after food. There have been no reported instances of extrapyramidal side effects.

When administered concomitantly with the anti-Parkinsonian drug, bromocriptine, domperidone has suppressed peripheral dose-limiting side effects (nausea and vomiting), thus enabling patients to tolerate higher doses of bromocriptine. Gastrointestinal symptoms induced by levodopa have also been alleviated by oral domperidone. The beneficial central effects of the anti-Parkinsonian drugs were not aggravated by domperidone, and extrapyramidal side effects attributable to domperidone were not reported.

Side Effects: Domperidone has been particularly well tolerated and has seldom caused any important side effects. There have been no extrapyramidal side effects reported during controlled therapeutic trials with domperidone, although a few anecdotal reports of such effects have been published.

Dosage: In adults with chronic postprandial dyspepsia the usual adult dose is 10mg 3 or 4 times daily before meals and at night. In children 0.3 mg/kg bodyweight is recommended. In acute vomiting requiring parenteral administration the daily dose should not exceed 1 mg/kg bodyweight. When administered rectally, the adult dosage is 60mg 2 to 4 times daily. In children younger than 2 years, a 10mg suppository should be inserted 2 to 4 times daily. In older children the usual daily rectal dose is 60mg in those aged 2 to 4 years, 90mg in those 4 to 6 years and 120mg in those over 6 years.

Adult patients with acute symptoms who are able to take the drug orally should be given 20 to 40mg 3 or 4 times daily. Children should receive 0.6 mg/kg 3 to 4 times daily.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agid, Y.; Pollak, P.; Bonnet, A.M.; Signoret, J.L. and Lhermitte, F.: Bromocriptine associated with a peripheral dopamine blocking agent in the treatment of Parkinson’s disease. Lancet 1: 570 (1979).PubMedGoogle Scholar
  2. Agid, Y.; Quinn, N. and Lhermitte, F.: Long term results of treatment of Parkinson’s disease with bromocriptine and domperidone. Revue Neurologique 137: 49 (1981).PubMedGoogle Scholar
  3. Agnoli, A.; Baldassarre, M.; Del Roscio, S.; Palesse, N. and Ruggieri, S.: Piribedil and Parkinson’s disease: Protection of peripheral side effects by domperidone; in Corsini and Gessa (Eds) Apomorphine and other Dophaminomimetics (Vol. 2) Clinical Pharmacology pp.117–122 (Raven Press, New York 1981).Google Scholar
  4. Agorastos, I.; Zissis, N.P.; Kaprinis, I. and Goulis, G.: Double-blind evaluation of domperidone in acute vomiting and dyspeptic disorders. Journal of International Medical Research 9: 143 (1981).PubMedGoogle Scholar
  5. Aono, T.; Shioji, T.; Aki, T.; Hirota, K.; Nomura, A. and Kurachi, K.: Augmentation of puerperal lactation by oral administration of sulpiride. Journal of Clinical Endocrinology and Metabolism 48: 478 (1979).PubMedGoogle Scholar
  6. Arts, E.; Anthoni, H.; de Roy, G.; D’Hollander, J. and Verhaegen, H.: Domperidone in the treatment of dyspepsia: A double-blind placebo-controlled study. Journal of International Medical Research 7: 158 (1979).PubMedGoogle Scholar
  7. Baeyens, R.; Reyntjens, A. and Van de Velde, E.: Effects of domperidone (R33812) on the motor function of the stomach and small intestine. Arzneimittel-Forschung 28(4): 682 (1978).PubMedGoogle Scholar
  8. Baeyens, R.; Van de Velde, E.; De Schepper, A.; Wollaert, F. and Reyntjens, A.: Effects of intravenous and oral domperidone on the motor function of the stomach and small intestine. Postgraduate Medical Journal 55(Suppl. 1): 19 (1979).PubMedGoogle Scholar
  9. Bateman, D.N.; Gooptu, D.; and Whittingham, T.A.: The effects of domperidone on gastric emptying of liquid in man. British Journal of Clinical Pharmacology 13: 675 (1982).PubMedGoogle Scholar
  10. Baudry, M.; Martres, M.P. and Schwartz, J.Ch.: 3H-Domperidone: A selective ligand for dopamine receptors. Naunyn-Schmiedeberg’s Archives of Pharmacology 308: 231 (1979).PubMedGoogle Scholar
  11. Bekhti, A. and Rutgeerts, L.: Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying. Postgraduate Medical Journal 55(Suppl. 1): 30 (1979).PubMedGoogle Scholar
  12. Bercovici, J.P.; Khoury, S.; Tater, D.; Caroff, J.; Sudre, Y. and Besson, G.: Domperidone: un nouvel agent pharmacodynamique pour l’exploration hypophysaire. Nouvelle Presse Medicale 10(29): 2421 (1981).PubMedGoogle Scholar
  13. Bernier, J. and Huys, J.: The effect of domperidone on the symptomatic treatment of radiotherapy-induced nausea and vomiting. Postgraduate Medical Journal 55(Suppl. 1): 52 (1979).Google Scholar
  14. Besser, G.M.; Delitala, G.; Grossman, A.; Stubbs, W.A. and Yeo, T.: Chlorpromazine, haloperidol, metoclopramide and domperidone release prolactin through dopamine antagonism at low concentrations but paradoxically inhibit prolactin release at high concentrations. British Journal of Pharmacology 71: 569 (1980).PubMedGoogle Scholar
  15. Blackwell, J.N.; Heading, R.C. and Fettes, M.R.: Effects of domperidone on lower oesophageal sphincter pressure and gastro-oesophageal reflux in patients with peptic oesophagitis. Progress with domperidone. Royal Society of Medicine International Congress and Symposium Series (No. 36) p.57 (1981).Google Scholar
  16. Boghaert, A.; Carron, D.; Gallant, J. and Stockman, A.: Postoperative vomiting treated with domperidone. A double-blind comparison with metoclopramide and a placebo. Acta Anaesthesiologica Belgica 31: 129 (1980).PubMedGoogle Scholar
  17. Bogaerts, M.; Braems, M. and Martens, C.: Domperidone in the prevention of L-dopa induced nausea. Postgraduate Medical Journal 55(Suppl. 1): 51 (1979).Google Scholar
  18. Boulanger, M.; Dubois, A. and Lecron, L.: Domperidone in the prevention of postoperative nausea and vomiting. Postgraduate Medical Journal 55(Suppl. 1): 45 (1979).PubMedGoogle Scholar
  19. Bourgeois, E.; Evenepoel, L.; Janssen, J.; Reyntjens, A.; Van Ganse, W. and Van De Mierop, L.: Domperidone (parenteral and oral) in the treatment of nausea and vomiting. Postgraduate Medical Journal 55(Suppl. 1): 50 (1979).Google Scholar
  20. Bouzo, H.: Double-blind comparison of domperidone and cimetidine in endoscopic healing of gastric ulcers (abstract). Gastroenterology 80 (No. 5, Part 2): 1115 (1981).Google Scholar
  21. Brassinne, A.; Linsmaux, D. and Merehie, G.: Intér êt de la mesure de la vitesse d’évacuation gastrique á la scinticámera. Acta Gastro-Enterologica Belgica 41: 688 (1978).PubMedGoogle Scholar
  22. Brock-Utne, J.G.: Domperidone antagonises the relaxant effect of atrophine on the lower esophageal sphincter. Anesthesia and Analgesia 59: 921 (1980).PubMedGoogle Scholar
  23. Brock-Utne, J.G.; Downing, J.W.; Dimopoulos, G.E.; Rubin, J. and Moshal, M.G.: Effect of domperidone on lower oesophageal sphincter tone in late pregnancy. Anesthesiology 52: 321 (1980).PubMedGoogle Scholar
  24. Broekaert, A.: Effect of domperidone on gastric empyting and secretion. Abstract 69, Proceedings of the 7th International Congress of Pharmacology, p.34 (Pergamon Press 1978).Google Scholar
  25. Broekaert, A.: Effect of domperidone on gastric emptying and secretion. Postgraduate Medical Journal 55(Suppl. 1): 11 (1979).PubMedGoogle Scholar
  26. Bron, B. and Massih, L.: Domperidone, a neuroleptic with powerful action on the lower oesophageal sphincter pressure. Digestion 20: 375 (1980).PubMedGoogle Scholar
  27. Brouwers, J.R.B.J.; Assies, J.; Wiersinga, W.M.; Huizing, G. and Tytgat, G.N.: Plasma prolactin levels after acute and sub-chronic oral administration of domperidone and of metoclopramide. Clinical Endocrinology 12: 435 (1980).PubMedGoogle Scholar
  28. Brown, G.M.; Verhaegan, H.; Van Wimersma Greidanus, T.B. and Brugmans, J.: Endocrine effects of domperidone: a peripheral dopamine blocking agent. Clinical Endocrinology 15: 275 (1981).PubMedGoogle Scholar
  29. Calvet, M.N.: Single blind crossover comparison of the gastrokinetic effects of clebopride and domperidone in patients with retarded gastric evacuation. Current Therapeutic Research 31 (Suppl.): 69 (1982).Google Scholar
  30. Camanni, F.; Genazzani, A.R.; Massara, F.; La Rosa, R.; Cocchi, D.; Müller, E.E.: Prolactin-releasing effect of domperidone in normoprolactinemic and hyperprolactinemic subjects. Neuroendocrinology 30: 2 (1980).PubMedGoogle Scholar
  31. Camanni, F.; Massara, F.; Santia, M. and Müller, E.E.: Impaired prolactive responsiveness to dopamine antagonists in acromegaly. Metabolism (In press 1982).Google Scholar
  32. Carter, D.A.; Pennington, J.M. and Whitehead, S.A.: In-vivo and in-vitro effects of domperidone on release of prolactin and LH in male and female rats. Journal of Reproduction and Fertility 64: 191 (1982).PubMedGoogle Scholar
  33. Casanueva, F.; Betti, R.; Cocchi, D.; Zanardi, P.; Motta, T. and Müller, E.E.: A role for dopamine in growth hormone regulation in the dog. Endocrinology 108: 1469 (1981).PubMedGoogle Scholar
  34. Cavagnini, F.; Benetti, G.; Invitti, C.; Ramella, G.; Pinto, M.; Lassa, M.; Dubini, A.; Marelli, A. and Müller, E.E.: Effect of gamma-aminobutyric acid (GABA) on growth hormone and prolactin secretion in man: Influence of pimozide and domperidone. Journal of Endocrinology and Metabolism 51: 789 (1980).Google Scholar
  35. Chantraine, J.M. and Reginster-Bous, M.: L’effet antiémétique de la domperidone (R33812) chez les enfants soumis a une cure cytotoxique. Revue Médicale de Liege 34: 199 (1979).PubMedGoogle Scholar
  36. Chey, W.Y.; Lee, K.Y. and Menguy, R.: Gastric dysrhythmia syndrome: Clinical characteristics, diagnosis and treatment. (Abstract.) Gastroenterology 80(5) p.1124 (1981).Google Scholar
  37. Chey, W.Y.; You, C.H. and Ange, D.A.: Open and double-blind clinical trials of domperidone in patients with unexplained nausea, vomiting, abdominal bloating and early satiety. Abstract of paper presented at a meeting of the American Gastroenterological Association at Chicago, May, 1982.Google Scholar
  38. Chuma, Y.: Clinical experience of domperidone on unidentified abdominal complaints. Shinryo to Shinyaku 17: 85 (1980).Google Scholar
  39. Cianchetti, C.; Masala, C.; Olivani, P.; Marrosu, G. and Gessa, G.L.: Sleep pattern modifications by dopamine agonists in man; in Corsini and Gessa (Eds). Apomorphine and other Dopaminomimetics Vol. 2: Clinical Pharmacology, pp. 173–181 (Raven Press, New York 1981).Google Scholar
  40. Clara, R.: Chronic regurgitation and vomiting treated with domperidone (R33812), a multicentre evaluation. Acta Paediatrica Belgica 32: 203 (1979).Google Scholar
  41. Clara, R.; Van Hollebeke, J. and Heck, E.: A multicentre pilot study of parenteral and rectal administration of domperidone in the treatment of severe vomiting in children. Postgraduate Medical Journal 55(Suppl. 1): 43 (1979).PubMedGoogle Scholar
  42. Cocchi, D.; Gil-Ad, I.; Parenti, M.; Stefanini, E.; Locatelli, V. and Müller, E.E.: Prolactin-releasing effect of a novel anti-dopaminergic drug, domperidone, in the rat. Neuroendocrinology 30: 65 (1980).PubMedGoogle Scholar
  43. Cooke, R.D.; Comyn, D.J. and Ball, R.W.: Prevention of postoperative nausea and vomiting by domperidone. A double-blind randomised study using domperidone, metoclopramide and a placebo. South African Medical Journal 56: 827 (1979).PubMedGoogle Scholar
  44. Corinaldesi, R.; Galassi, A.; Calamelli, R.; Zarabini, G.E.; Stanghellini, V. and Barbara, L.: Domperidone promotes the gastric emptying of both solid and liquid phases of a mixed meal, (unpublished data).Google Scholar
  45. Corsini, G.U.; Del Zompo, M.; Gessa, GL. and Mangoni, A.: Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson’s disease. Lancet 1: 954 (1979).PubMedGoogle Scholar
  46. Corsini, G.U.; Piccardi, M.P.; Bocchetta, A.; Bernardi, F. and Del Zompo, M.: Behavioural effects of apomorphine in man: Dopamine receptor implications in Corsini and Gessa (Eds) Apomorphine and other Dopaminomimetics Vol. 2: Clinical Pharmacology pp. 13–24 (Raven Press, New York 1981).Google Scholar
  47. Costall, B.; Fortune, D.H. and Naylor, R.J.: Neuropharmacological studies on the neuroleptic potential of domperidone (R33812). Journal of Pharmacy and Pharmacology 31: 344 (1979).PubMedGoogle Scholar
  48. D’Agata, R.; Aliffi, A.; Vicari, D.; Volpicelli, D.; Mongiol, A. and Gulizia, S.: Some critical considerations on the use of the nomifensine test in the hyperprolactinaemic syndrome. Hormone Research 14: 148 (1981).PubMedGoogle Scholar
  49. Debontridder, O.: Extrapyramidal reactions due to domperidone. (Letter) Lancet 1: 802 (1980).Google Scholar
  50. Decraene, A.: A controlled crossover study of domperidone, metoclopramide and placebo in the treatment of haemodialysis-associated vomiting. Postgraduate Medical Journal 55(Suppl. 1): 52 (1979).Google Scholar
  51. Delitala, G.; Devilla, L. and Lottli, G.: Domperidone an extracerebral inhibitor of dompamine receptors, stimulates thyrotrophin and prolactin release in man. Journal of Clinical Endocrinology and Metabolism 50: 1127 (1980).PubMedGoogle Scholar
  52. De Loore, I.; Van Ravensteyn, H. and Ameryckx, L.: Domperidone drops in the symptomatic treatment of chronic paediatric vomiting and regurgitation. A comparison with metoclopramide. Postgraduate Medical Journal 55(Suppl. 1): 40 (1979).PubMedGoogle Scholar
  53. De Loose, F.: Domperidone in chronic dyspepsia: A pilot open study and a multicentre general practice crossover comparison with metoclopramide and placebo. Pharmatherapeutics 2: 140 (1979).Google Scholar
  54. De Meester, J.: The effect of domperidone on nausea and vomiting caused by head injury and intra-cranial lesions. Postgraduate Medical Journal 55(Suppl. 1): 51 (1979).Google Scholar
  55. Denef, C. and Folleboucket, J.-J.: Differential effects of dopamine antagonists on prolactin secretion from cultured rat pituitary cells. Life Sciences 23: 431 (1978).PubMedGoogle Scholar
  56. Depuydt, L.; Geens, H.; Lambrecht, A.; Sandra, M. and Schiettekatte, L.: Effect of domperidone on the gastric tolerance and the efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis. Postgraduate Medical Journal 55(Suppl. 1): 52 (1979).Google Scholar
  57. De Schepper, A.; Wollaert, F. and Reyntjens, A.: Effects of oral domperidone on gastric empyting and motility. Arzneimittel-Forschung 28(7): 1196 (1978).PubMedGoogle Scholar
  58. Dhondt, F.; Traen, S.; Van Eygen, M.; Baran, D.; Willaert, H.; Delobel, L. and Van Oproy, F.: Domperidone (R33812) suppositories: An effective antiemetic agent in diverse pediatric conditions. A multicentre trial. Current Therapeutic Research 24: 912 (1978).Google Scholar
  59. D’Souza, D.P.; Reyntjens, A. and Thornes, R.D.: Domperidone in the prevention of nausea and vomiting induced by antineoplastic agents: A three-fold evaluation. Current Therapeutic Research 27: 384 (1980).Google Scholar
  60. Dunne, M.J.; Walker, J.; Cowden, E.A. and Ratcliffe, J.G.: Nomifensine test for investigation of hyperprolactinaemia. Lancet 2: 1243 (1979).PubMedGoogle Scholar
  61. Englert, W. and Schlich, D.: A double-blind crossover trial of domperidone in chronic postprandial dyspepsia. Postgraduate Medical Journal 55(Suppl. 1): 28 (1979).PubMedGoogle Scholar
  62. Ennis, C. and Cox, B.: The dopamine receptor antagonist domperidone is also a competitive antagonist at α 1-adrenoceptors. Journal of Pharmacy and Pharmacology 32: 434 (1980).PubMedGoogle Scholar
  63. Ennis, C.; Lee, T.-F. and Cox, B.: Relative potency of domperidone and a series of centrally active dopamine antagonists on apomorphine induced hypothermia in the mouse and the rat; in Cox et al. (Eds) Thermoregulatory Mechanism and Their Therapeutic Implications, pp.24–25 (Kargon, New York 1980).Google Scholar
  64. Eyre-Brook, I.A.; Linhardt, G.E. and Johnson, A.G.: Effects of domperidone on antroduodenal motor activity in man: A double-blind study with a new technique. Abstract of a paper presented at the Surgical Research Society Meeting January 8th (1982).Google Scholar
  65. Falk, R.H.; Desilva, R.D. and Lown, B.: Reduction in vulnerability to ventricular fibrillation by bromocriptine, a dopamine agonist. Cardiovascular Research 15: 175 (1981).PubMedGoogle Scholar
  66. Fragen, R.J. and Caldwell, N.: A new benzimidazole antiemetic, domperidone, for the treatment of postoperative nausea and vomiting. Anesthesiology 49: 289 (1978).PubMedGoogle Scholar
  67. Fujino, T.; Kato, H.; Yamashita, S.; Aramaki, S.; Morioka, H.; Koresaura, M.; Miyauchi, F.; Toyoshima, H. and Torigol, T.: Effects of domperidone on serum prolactin levels in human beings. Endocrinologia Japonica 27: 521 (1980).PubMedGoogle Scholar
  68. Gomi, K.: Effect of domperidone on unidentified gastrointestinal complaints in gastric/duodenal ulcer patients. Kiso to Rinsho 14: 282 (1980).Google Scholar
  69. Gordon, S.J. and Joseph, R.E.: Domperidone in patients with postprandial upper gastrointestinal distress. Progress with domperidone. Royal Society of Medicine. International Congress and Symposium Series (No. 36) p.67 (1981).Google Scholar
  70. Grimes, J.D.; Hassan, M.N. and Preston, D.N.: Adverse neurologic effects of metoclopramide. Canadian Medical Association Journal 126: 23 (1982).PubMedGoogle Scholar
  71. Grimes, J.D.; Parkinsonism and tardive dyskinesia associated with long term metoclopramide therapy. New England Journal of Medicine 305: 1417 (1981).PubMedGoogle Scholar
  72. Guzman, V.; Toscano, G.; Canales, E.S. and Zárate, A.: Improvement of defective lactation by using oral metoclopramide. Acta Obstetrica et Gynaecologica Scandinavica 58: 53 (1979).Google Scholar
  73. Haarmann, K.; Lebkuchner, F.; Widmann, A.; Kief, W. and Esslingen M.: A double-blind study of domperidone in the symptomatic treatment of chronic post-prandial upper gastrointestinal distress. Postgraduate Medical Journal 55(Suppl. 1): 24 (1979).PubMedGoogle Scholar
  74. Haase, H.J.; Kaumeier, S.; Schwarz, H.; Gundel, A.; Linde, O.K.; Schnabele, E. and Stripf, L.: Domperidone: A preliminary evaluation of a potential antiemetic. Current Therapeutic Research 23: 702 (1978).Google Scholar
  75. Hamers, J.: Cytostatic therapy induced vomiting inhibited by domperidone. A double-blind cross-over study. Biomedicine 29: 242 (1978).PubMedGoogle Scholar
  76. Hanson, M. and Plichart, P.: The use of domperidone as premedication for oesophagogastroscopy. Postgraduate Medical Journal 55(Suppl. 1): 52 (1979).Google Scholar
  77. Harasawa, S. and Miwa, T.: Effects of domperidone on gastric emptying in man. A placebo-controlled evaluation. Naika Hokan 28(3): 67 (1981).Google Scholar
  78. Healy, D.L. and Burgen, H.G.: Increased prolactin and thyotropin secretion following oral metoclopramide: dose response relationship. Clinical Endocrinology 7: 195 (1977).PubMedGoogle Scholar
  79. Heer, M.; Pirovino, M.; Japp, H.; Bühler, H. and Schmid, M.: Diabetic gastroparesis and colonic dilatation treated with domperidone. Lancet 2: 1145–1146 (1980).PubMedGoogle Scholar
  80. Helmers, J.H.J.H. and Van Leeuwen, L.: Domperidone (R33812) as an antiemetic in the treatment of postoperative vomiting. A double-blind comparison between two different dosages (4 and 10mg). Acta Anaesthesiologica Belgica 30: 265 (1979).PubMedGoogle Scholar
  81. Heykants, J.; Hendriks, R.; Meuldermans, W.; Michiels, M.; Scheygrond, H. and Reyntjens, H.: On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. European Journal of Drug Metabolism and Pharmacokinetics 6: 61 (1981b).PubMedGoogle Scholar
  82. Heykants, J.; Knaeps, A.; Meuldermans, W. and Michiels, M.: On the pharmacokinetics of domperidone in animals and man. I. Plasma levels of domperidone in rats and dogs. Age related absorption and passage through the blood brain barrier in rats. European Journal of Drug Metabolism and Pharmacokinetics 6: 27 (1981a).PubMedGoogle Scholar
  83. Hilland, U.; Bohnet, H.G. and Blank, M.: Domperidone stimulated prolactin secretion in normal male and female volunteers. Endokrinologie 77: 363 (1981).PubMedGoogle Scholar
  84. Huizing, G.; Brouwers, J.R.B.J. and Westhuis, P.: Plasma drug concentration and prolactin release after acute and sub-chronic oral administration of domperidone and metoclopramide; in Merkus (Ed.) The Serum Concentration of Drugs, pp.271–277 (Exerpta Medica, Amsterdam 1980).Google Scholar
  85. Huys, J.: Cytostatic-associated vomiting effectively inhibited by domperidone (R33812). Cancer Chemotherapy and Pharmacology 1: 215 (1978).PubMedGoogle Scholar
  86. Jacobs, F.; Akkermans, L.M.A.; Yol, O.H. and Wittebol, P.: Effects of domperidone on gastric emptying of semi-solid and solid food. Progress with Domperidone. Royal Society of Medicine International Congress and Symposium Series (No. 36) pp.11–19 (1981).Google Scholar
  87. Jaecques, N.; Lambrecht, A.; Schiettekatte, L. and Waelkens, J.: Treatment of nausea and vomiting during migraine attacks with intravenous domperidone. Postgraduate Medical Journal 55(Suppl. 1): 51 (1979).Google Scholar
  88. Johnson, A.G.: Flatulent dyspepsia. Postgraduate Medical Journal 49(Suppl. 4): 104 (1973).PubMedGoogle Scholar
  89. Joss, R.; Galeazzi, R.; Goldhirsch, A.; Ryssel, H.J. and Brunner, K.: Phase-I trial of the antiemetic domperidone as a continuous infusion in patients receiving cancer chemotherapy. Abstract of paper presented at Congress UICC, Conference on Clinical Oncology, Lausanne, Switzerland, Oct 28–31 (1981).Google Scholar
  90. Joss, R.A.; Goldhirsch, A.; Brunner, K.W. and Galeazzi, R.L.: Sudden death in cancer patient on high dose domperidone. Lancet 1: 1019 (1982).PubMedGoogle Scholar
  91. Kamijo, K.; Saito, A.; Suzuki, M. and Wada, T.: Effect of domperidone on prolactin secretion. Igaku No Ayumi 110: 683 (1979).Google Scholar
  92. Kauppila, A.; Kivinen, S. and Ylikorkala, O.: A dose response relation between improved lactation and metoclopramide. Lancet 1: 1175 (1981).PubMedGoogle Scholar
  93. Kataria, M.; Traub, M. and Marsden, C.D.: Extrapyramidal side effects of metoclopramide. Lancet 2: 1254 (1978).PubMedGoogle Scholar
  94. Kaufman, J.M.; Elewant, A. and Vermeulen, A.: Effect of domperidone on prolactin (PRL) and thyrotrophin (TSH) secretion. Archives Internationales de Pharmacodynamie et de Therapie 254: 293 (1981).PubMedGoogle Scholar
  95. Kendler, K.S.; Heninger, G.R. and Roth, R.H.: Brain contribution to the haloperidol-induced increase in plasma homovanillic acid. European Journal of Pharmacology 71: 321 (1981).PubMedGoogle Scholar
  96. Kessler, E.; Bremner, C.H. and Bremner, C.G.: The effect of intravenous domperidone on the resting lower oesophageal sphincter pressure in dogs and baboons. South African Medical Journal, Oct 679 (1979).Google Scholar
  97. Korttila, K.; Kauste, A. and Auvinen, J.: Comparison of domperidone, droperidol and metoclopramide in the prevention and treatment of nausea and vomiting after balanced anesthesia. Anesthesia and Analgesia 58: 396 (1979).PubMedGoogle Scholar
  98. Kubo, K.: Effect of domperidone on the gastrointestinal symptoms induced by anticancer agents. Shinryo to Shinyaku 17: 153 (1980).Google Scholar
  99. Laduron, P. and Leysen, J.: Domperidone, a novel gastrokinetic and anti-nauseant drug, interacts selectively with dopamine receptors. Abstract of Paper presented at the 7th International Congress of Pharmacology, Paris, 1978.Google Scholar
  100. Laduron, P.M. and Leysen, J.E.: Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochemical Pharmacology 28: 2161 (1979).PubMedGoogle Scholar
  101. Lavy, S.; Melamed, E. and Penchat, S.: Tardive dyskinesia associated with metoclopramide. British Medical Journal 1: 77 (1978).PubMedGoogle Scholar
  102. Lazareno, S. and Nahorski, S.R.: A comparative study of 3H-domperidone and 3H-spiperone binding in the rat striatum. British Journal of Pharmacology 74: 231P (1981).Google Scholar
  103. Leeuwen, Van L. and Helmers, J.H.J.H.: The efficacy of domperidone (R33812) in the treatment of postoperative vomiting. Anaesthesist 29: 490 (1980).PubMedGoogle Scholar
  104. Lienard, J.; Janssen, J.; Verhaegen, H.; Burgeois, E. and Willcox, R.: Oral domperidone (R33812) in the treatment of chronic dyspepsia: A multicentre evaluation. Current Therapeutic Research 23: 529 (1978).Google Scholar
  105. Lux, G.; Engel, H. and Rösch, W.: The stimulation of oesophageal motility with bromopride, domperidone and metoclopramide. Progress with Domperidone, Royal Society of Medicine. International Congress and Symposium Series (No. 36) p.29 (1981).Google Scholar
  106. Madangopalan, N.; Ravi, N.; Ravi, V.V. and Raghuram, K.: Clinical evaluation of efficacy of domperidone in reflux oesophagitis and non-ulcer dyspepsia. Indian Practitioner 34(7): 481 (1981).Google Scholar
  107. Malagelada, J.-R.: Physiologic basis and clinical significance of gastric emptying disorders. Digestive Diseases and Sciences 24: 657 (1979).PubMedGoogle Scholar
  108. Malmud, L.S.; Fisher, R.S.; Knight, L.C. and Rock, E.: Scintigraphic evaluation of gastric emptying. Seminars in Nuclear Medicine 12: 116 (1982).PubMedGoogle Scholar
  109. Martres, M.P.; Baudry, M. and Schwartz, J.Ch.: Characterization of H-domperidone binding on striatal dopamine receptors. Life Sciences 23: 1781 (1978).PubMedGoogle Scholar
  110. Massara, F.; Camanni, F.; Belforte, L.; Vergano, V. and Molinatti, G.M.: Increased thyrotrophin secretion induced by sulpiride in man. Clinical Endocrinology 9: 419 (1978).PubMedGoogle Scholar
  111. Massara, F.; Camanni, F.; Amoroso, A.; Molinatti, G.M. and Müller, E.E.: Increased thyrotrophin and prolactin secretion induced by domperidone in hypothyroid subjects. Acta Endocrinologica 97: 48 (1981b).PubMedGoogle Scholar
  112. Massara, F.; Genazzani, A.R.; Camanni, F.; De Leo, V.; Molinatti, G.M. and Müller, E.E.: Tests of prolactin secretion in the diagnosis of hyperprolactinemic states: Nomifensine and domperidone. Fertility and Sterility 35: 149 (1981a).PubMedGoogle Scholar
  113. Meuldermans, W.; Hurkmans, R.; Swysen, E.; Hendrickx, J.; Michiels, M.; Lauwens, W. and Heykants, J.: On the pharmacokinetics of domperidone in animals and man. III. Comparative study on the secretion and metabolism of domperidone in rats, dogs and man. European Journal of Drug Metabolism and Pharmacokinetics 6: 49 (1981).PubMedGoogle Scholar
  114. Michiels, M.; Hendriks, R. and Heykants, J.: On the pharmacokinetics of domperidone in animals and man. II. Tissue distribution, placental and milk transfer of domperidone in the Wistar rat. European Journal of Drug Metabolism and Pharmacokinetics 6: 37 (1981).PubMedGoogle Scholar
  115. Milo, R.: Use of the peripheral dopamine antagonist domperidone, in the management of gastrointestinal symptoms in patients with irritable bowel syndrome. Current Medical Research and Opinion 6: 577 (1980).PubMedGoogle Scholar
  116. Molinatti, G.M.; Camanni, F.; Cocchi, D.; De Leo, V.; Genazzani, A.R.; Massana, F. and Müller, E.E.: Approach to the diagnosis of hyperprolactinemic states: The nomifensine and domperidone tests. Panminerva Medica 23: 5 (1981).PubMedGoogle Scholar
  117. Moriga, M.: A multicentre double-blind study of domperidone and metoclopramide in the symptomatic control of dyspepsia. Progress with domperidone. Royal Society of Medicine International Congress and Symposium Series (No. 36) p.77 (1981).Google Scholar
  118. Müller, E.E.; Genazzani, A.R.; Camanni, F.; Cocchi, D.; Massara, F.; Picciolini, E.; Locatelli, V. and Molinatti, G.M.: Neuropharmacologic approach to the diagnosis and treatment of pituitary secreting adenomas. Presented at International Symposium on Pituitary Microadenomas, Milan (1978).Google Scholar
  119. Munehisa, T.: Effect of domperidone on liver cancer patients with gastrointestinal symptoms induced by anticancer agents. Igaku to Yakugaku 3: 87 (1980).Google Scholar
  120. Murakami, M.: Preventative effect of domperidone on the side effects of cancer chemotherapy such as nausea and vomiting. (Abstract.) Paper presented at the 17th Annual Meeting of Japan Society for Cancer Therapy, Tokyo (1979).Google Scholar
  121. Muroaka, T.; Kawakami, A.; Nomiyama, H.; Sesoko, M. and Tsuneoka, K.: LESP-increasing factors, especially those in the form of drugs. Paper presented at the 65th Congress of the Japanese Society of Gastroenterology, Tokyo (1979).Google Scholar
  122. Nagaoka, M.: Effect of domperidone (KW5338) on gastrointestinal symptoms caused by L-dopa. Shinyaku to Rinsho 29: 2 (1980).Google Scholar
  123. Nagler, J. and Miskovitz, P.: Clinical evaluation of domperidone in the treatment of chronic postprandial idiopathic upper gastrointestinal distress. American Journal of Gastroenterology 76: 495 (1981).PubMedGoogle Scholar
  124. Nagura, E.: Effect of KW5338 (domperidone) on nausea and vomiting induced by anticancer agents. Gan no Rinsho 26: 889 (1980).Google Scholar
  125. Niemegeers, C.J.E.; Schellekens, K.H.L. and Janssen, P.A.J.: The antiemetic effects of domperidone, a novel potent gastrokinetic. Archives Internationales de Pharmacodynamie et de Therapie 244: 130 (1980).PubMedGoogle Scholar
  126. Nogarède, J.; Closon, M.Th.; Clarysse, A.; Longueville, J.; Derouaux, M.; Ferrant, A. and Drochmans, A.: Domperidone (R33812) in the prophylactic treatment of chemotherapy-induced emesis. Arzneimittel-Forschung 28: 686 (1978).PubMedGoogle Scholar
  127. Nomura, K. and Iwasa, T.: Clinical investigation of domperidone on gastrointestinal tract disease. Shinryo to Shinyaku 16: 131 (1979).Google Scholar
  128. O’Meara, A. and Mott, G.: Domperidone as an antiemetic in paediatric oncology. Cancer Chemotherapy and Pharmacology 6: 147 (1981).PubMedGoogle Scholar
  129. O’Shea, M.: A double-blind comparison of domperidone and metoclopramide in the treatment of postprandial dyspeptic symptoms. Current Therapeutic Research 28: 367 (1980).Google Scholar
  130. Platteborse, R.; Hermans, C.; Loots, W.; Van Loon, J.; Van Gorp, A.; Smet, F. and Jageneau, A.: The effect of domperidone on pyloric activity in dog and man. Postgraduate Medical Journal 55(Suppl. 1): 15 (1979).PubMedGoogle Scholar
  131. Pinder, R.M.; Brogden, R.N.; Sawyer, P.R.; Speight, T.M. and Avery, G.S.: Metoclopramide: A review of its pharmacological properties and clinical use. Drugs 12(2): 81 (1976).PubMedGoogle Scholar
  132. Pollak, P.; Gaio, J.M.; Hommel, M.; Pellat, J. and Chateau, R.: Étude arguä de l’association bromocriptine et domperidone dans le syndrome parkinsonién. Thérapie 36: 671 (1981).PubMedGoogle Scholar
  133. Pourmand, M.; Rodrigue-Arnao, M.D.; Weightman, D.R.; Hall, R.; Cook, D.B.; Lewis, M. and Scanion, M.F.: Domperidone: a novel agent for the investigation of anterior pituitary function and control in man. Clinical Endocrinology 12: 211 (1980).PubMedGoogle Scholar
  134. Proctor, J.D.; Fratkin, M.J.; Evans, E.F. and Wasserman, A.J.: Effect of domperidone on apomorphine retarded gastric emptying. Progress with Domperidone, Royal Society of Medicine. International Congress and Symposium Series (No. 36) p.37 (1981).Google Scholar
  135. Quinn, N.; Illas, A.; Lhermitte, F. and Agid, Y.: Bromocriptine and domperidone in the treatment of Parkinson disease. Neurology 31: 662 (1981).PubMedGoogle Scholar
  136. Remeysen, P.; Wouters, L. and Xhonneux, R.: Long lasting intravenous infusion of domperidone in anaesthetised dogs: Effects on ECG and blood pressure. Data on File, Janssen Pharmaceutica Research Laboratories.Google Scholar
  137. Saez, J.M.E. and Cirera, A.C.: Double-blind parallel comparison of the gastrokinetic effects of clebopride, domperidone and placebo in human volunteers with gastric stasis induced by glucagon. Current Therapeutic Research 31 (Suppl.): 58 (1982).Google Scholar
  138. Sáenz, V.; Ramos, H. and Morales, P.: Evaluación de clinica domperidona en ciertas formas de dispepsia. Investigaci ón Médica Internaci ónal 7: 318 (1980).Google Scholar
  139. Sahyoun, H.A.; Costall, B. and Naylor, R.J.: Catecholamine-induced relaxation and contraction of the lower oesophageal and pyloric sphincters of guinea-pig stomach: modification by domperidone. Journal of Pharmacy and Pharmacology 34: 318 (1982).PubMedGoogle Scholar
  140. Scanion, M.F.; Weightman, D.R.; Mora, B.; Heath, M.; Shale, D.J.; Snow, M.H. and Hall, R.: Evidence for dopaminergic control of thyrotrophin secretion in man. Lancet 2: 421 (1977).Google Scholar
  141. Schulze-Delrieu, K.; Summers, R.W. and Finke, D.: Domperidone in reflux oesophagitis and gastric stasis. (Letter to the Editor.) Lancet 1: 159 (1981).PubMedGoogle Scholar
  142. Schuurkes, J.A.J, and Van Nueten, J.M.: Is dopamine an inhibtory modulator of gastrointestinal motility? Scandinavian Journal of Gastroenterology 16(Suppl. 67): 33 (1981a).Google Scholar
  143. Schuurkes, J.A.J. and Van Nueten, J.M.: Effects of dopamine and its antagonist domperidone cannot be explained by an effect of α 1-adrenergic receptors. Archives Internationales de Pharmacodynamic et de Therapie 250: 324 (1981b).Google Scholar
  144. Schuurkes, J.A.J.; Helsen, L.F.M. and Van Nueten, J.M.: Improved gastroduodenal coordination by the peripheral dopamine-antagonist domperidone; in Wienbeck (Ed.) Motility of the Digestive Tract, pp.565–572 (Raven Press, New York 1982).Google Scholar
  145. Schuurkes, J.A.J, and Van Nueten, J.M.: Dose dependent stimulation of antroduodenal coordination by domperidone via specific dopamine-receptors. Archives Internationales de Pharmacodynamie et de Therapie 256: 311 (1982).PubMedGoogle Scholar
  146. Segrestaa, J.M.; Gueris, J.; Julien, D. and Tiar, M.: Hyperprolactinémie des anti-émétiques. Therapie 34: 437 (1979).PubMedGoogle Scholar
  147. Shuto, K.; Shiozaki, S.; Kojima, T. and Tanaka, M.: Antagonism of KW-5338 (domperidone) against emesis and depression of intestinal motility induced by L-dopa. Journal of Pharmacobio-Dynamics 3: 709 (1980).PubMedGoogle Scholar
  148. Sinnett, H.D. and Leathard, H.L.: Domperidone: its effect on human gastric adaptive relaxation. Progress with domperidone. Royal Society of Medicine International Congress and Symposium Series No. 36, p.43 (1981).Google Scholar
  149. Sitsen, J.M.A. and Brouwers, J.R.B.J.: Lactation improvement by tablets? (in Dutch). Pharmaceutisch Weekblad 115: 629 (1980).Google Scholar
  150. Sol, P.; Pelet, B. and Guignard, J.-P.: Extrapyramidal reactions due to domperidone. (Letter.) Lancet 2: 802 (1980).Google Scholar
  151. Sowers, J.R.; Sharp, B. and McCallum, R.W.: Effect of domperidone, an extracerebral of dopamine receptors, thyrotrophin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man. Journal of Clinical Endocrinology and Metabolism 54: 869 (1982).PubMedGoogle Scholar
  152. Stockman, A.; Caron, D.; Gallant, J. and Boghaert, A.: Postoperative nausea and vomiting treated with domperidone (R33812). Anaesthesist 27: 540 (1978).PubMedGoogle Scholar
  153. Sugiura, H. and Kasugai, T.: Effect of domperidone on the side effects of anti-cancer drugs. Shinryo to Shinyaku 17: 67 (1980).Google Scholar
  154. Suyama, T. and Miyoshi, A.: Clinical and experimental studies on the effect of domperidone on gastric emptying rate. Japanese Archives of Internal Medicine 27(12): 367 (1980).Google Scholar
  155. Swann, I.L.; Thompson, E.N. and Qureshi, K.: Domperidone or metoclopramide in preventing chemotherapeutically induced nausea and vomiting. British Medical Journal 2: 1188 (1979).PubMedGoogle Scholar
  156. Uberti, E.C.; Trasforini, G.C.; Margutti, A.R. and Sammaroli, S.R.: Effect of domperidone on prolactin secretion in healthy subjects. Panminerva Medica 22: 13 (1980).PubMedGoogle Scholar
  157. Uberti, E.C.D.; Trasforini, G.C.; Margutti, A.R.; Sammaroli, S.R.; Fersini, C. and Pansini, R.: Plasma aldosterone response to domperidone, an extracerebral dopamine receptor blocker, in normal subjects. Panminerva Medica 23: 183 (1981).PubMedGoogle Scholar
  158. Umeda, N. and Sakagami, R.: Clinical experience of domperidone in patients with gastrointestinal disease. Kiso to Rinsho 10: 275 (1980).Google Scholar
  159. Valenzuela, J.E.: Effects of domperidone on the symptoms of reflux oesophagitis. Progress with Domperidone. Royal Society of Medicine. International Congress and Symposium Series (No. 36) p.51 (1981).Google Scholar
  160. Valenzuela, J.E.; Defilippi, C. and Gutierrez, F.: Effect of domperidone on patients with symptomatic gastro-oesophageal reflux. (Abstract.) Digestive Diseases and Sciences 25(9): 716 (1980).Google Scholar
  161. Valenzuela, J.E. and Liu, D.P.: The effect of variations in intragastric pressure and gastric emptying of a saline meal in man. Paper presented at the 8th International Symposium on Gastrointestinal Motility, Germany (1981).Google Scholar
  162. Valenzuela, J.E.; Miranda, M.; Ansari, A.N. and Lim, B.R.: Delayed gastric emptying in patients with reflux esophagitis. Abstract of paper presented at meeting of the American Gastroenterological Association (May, 1981).Google Scholar
  163. Van de Mierop, L.; Rutgeerts, L.; Van den Langenbergh, B. and Staessen, A.: Oral domperidone in chronic postprandial dyspepsia. Digestion 19: 244 (1979).PubMedGoogle Scholar
  164. Van Eygen, M.; Dhondt, F.; Heck, E.; Ameryckx, L. and Van Ravensteyn, H.: A double-blind comparison of domperidone and metoclopramide suppositories in the treatment of nausea and vomiting in children. Postgraduate Medical Journal 55(Suppl. 1): 36 (1979).PubMedGoogle Scholar
  165. Van Eygen, M.; Traen, S.; Van Ravensteyn, H.; Goethals, C.; Van de Mierop, L.; Milo, R. and Rutgeerts, L.: A double-blind, placebo controlled study to assess the efficacy of domperidone in the treatment of acute nausea and vomiting. Clinical Research Reviews 1: 211 (1981).Google Scholar
  166. Van Ganse, W.; Van Damme, L.; Van de Mierop, L.; Deruyttere, M.; Lauwers, W. and Coenegrachts, J.: Chronic dyspepsia: Double blind treatment with domperidone (R33 812) or a placebo. A multicentre therapeutic evaluation. Current Therapeutic Research 23: 695 (1978).Google Scholar
  167. Van Mierlo, F. and Van de Mierop, L.: Anti-emetic treatment with domperidone suppositories in geriatric patients. Postgraduate Medical Journal 55(Suppl. 1): 51 (1979).Google Scholar
  168. Van Nueten, J.M.: Is dopamine an inhibitory modulator of gastric motility. Trends in Pharmacological Sciences. P.233 (May 1980).Google Scholar
  169. Van Nueten, J.M.; Ennis, C.; Helsen, L.; Laduron, P.M. and Janssen, P.A.J.: Inhibition of dopamine receptors in the stomach; an explanation of the gastrokinetic properties of domperidone. Life Sciences 23: 453 (1978).PubMedGoogle Scholar
  170. Van Nueten, J.M. and Janssen, P.A.: Is dopamine an endogenous inhibitor of gastric emptying; in Duthie (Ed.) Gastrointestinal Motility in Health and Disease pp. 173–180 (MTP, 1978).Google Scholar
  171. Van Nueten, J.M. and Janssen, P.A.J.: Effect of domperidone on gastric relaxation caused by dopamine, secretin, 5-hydroxytryptamine, substance P, and adenosine triphosphate in Christensen (Ed.) Gastrointestinal Motility, pp.225–231 (Raven Press, New York 1980).Google Scholar
  172. Van Nueten, J.M. and Schuurkes, J.A.J.: Animal pharmacology of domperidone, antiemetic and gastrokinetic properties. Progress with domperidone. Royal Society of Medicine International Congress and Symposium Series No. 36, p.22 (1981).Google Scholar
  173. Waelkens, J.: Domperidone in the prevention of complete classical migraine. (Letter.) British Medical Journal 284: 944 (1982).PubMedGoogle Scholar
  174. Wanquier, A.; Niemegeers, C.J.E. and Janssen, P.A.J.: Neuropharmacological comparison between domperidone and metoclopramide. Japanese Journal of Pharmacology 31: 305 (1981a).Google Scholar
  175. Wanquier, A.; Van Den Broeck, W.A.E. and Niemegeers, C.J.E.: On the antagonistic effects of pimozide and domperidone on apomorphine-disturbed sleep-wakefulness in dogs; in Koella (Ed.) Sleep 1980, Proceedings of the 5th European Congress on Sleep Research, Amsterdam, pp.279–282 (Karger, Basel 1981b).Google Scholar
  176. Weihrauch, T.R. and Ehl, W.: Effect of domperidone on the motility of antrum, pylorus and duodenum in man. Scandinavian Journal of Gastroenterology (Suppl. 67): 195 (1981).Google Scholar
  177. Weihrauch, T.R. and Ewe, K.: A controlled double-blind trial of the effect of domperidone on the healing of benign gastric ulceration. Progress with domperidone. Royal Society of Medicine. International Congress and Symposium Series (No. 36) p.89 (1981).Google Scholar
  178. Weihrauch, T.R.; Forster, C.R.F. and Krieglstein, J.: Evaluation of the effect of domperidone on human oesophageal and gastroduodenal motility by intraluminal manometry. Postgraduate Medical Journal 55(Suppl. 1): 7 (1979).PubMedGoogle Scholar
  179. Willems, J.L.; Bogaert, M.G. and Buylaert, W.: Preliminary observations on the interaction of domperidone with peripheral dopamine receptors. Japanese Journal of Pharmacology 31: 131 (1981).PubMedGoogle Scholar
  180. Wilson, D.B. and Dundee, J.W.: Evaluation of the antiemetic action of domperidone. Anaesthesia 34: 765 (1979).PubMedGoogle Scholar
  181. Zegveld, C.; Knape, H.; Smits, J.; Belopavlovic, M.; Caron, D.; Gallant, J.; Stockman, A. and Boghaert, A.: Domperidone in the treatment of postoperative vomiting. A double-blind multicentre study. Anesthesia and Analgesia 57: 700 (1978).PubMedGoogle Scholar
  182. Zissis, N.P.; Zouboulis-Vafiadis, I.; Dispyraki-Seidon, K. and Daikos, G.K.: Domperidone, a peripheral domperidone blocker, in acute nausea and vomiting. Current Therapeutic Research 26: 402 (1979).Google Scholar
  183. Zylberait, D.; Krulik, M.; Audebert, A.A. and Debray, J.: Essai comparatif de deux medicaments dans le traitement des vomissements induits par la chimiotherapie anti-cancereux. Semaine des Hopitaux 57: 47 (1981).PubMedGoogle Scholar

Copyright information

© ADIS Press Australasia Pty Ltd (Inc. NSW) 1982

Authors and Affiliations

  • R. N. Brogden
    • 1
    • 2
  • A. A. Carmine
    • 1
    • 2
  • R. C. Heel
    • 1
    • 2
  • T. M. Speight
    • 1
    • 2
  • G. S. Avery
    • 1
    • 2
  1. 1.ADIS Drug Information ServicesBirkenhead, Auckland 10New Zealand
  2. 2.ADIS Drug Information ServicesNew YorkUSA

Personalised recommendations